Table 6.
ASXL1, JAK2, and TET2 Mutations and the Rates of Transformation to AML
| Gene | PMF |
PV |
ET |
|||
|---|---|---|---|---|---|---|
| Mutated, No. | AML, No. (%) | Mutated, No. | AML, No. (%) | Mutated, No. | AML, No. (%) | |
| ASXL1 | 18 | 3 (16.67) | 2 | 0 (0.00) | 2 | 0 (0.00) |
| JAK2 | 39 | 1 (2.56) | 31 | 2 (6.45) | 17 | 1 (5.88) |
| TET2 | 12 | 0 (0.00) | 6 | 0 (0.00) | 2 | 0 (0.00) |
AML, acute myeloid leukemia; ET, essential thrombocytosis; PMF, primary myelofibrosis; PV, polycythemia vera.
a
ASXL1, JAK2, and TET2 are not mutually exclusive. Comutations of these three genes in this study in patients with at least one of these three mutations are 28.3% in PMF, 25.81% in PV, and 5% in ET. The numbers of patients were too small for statistical analysis. Of the patients who had disease that transformed into AML, only one patient showed a comutation (ASXL1 and JAK2).